Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a randomized trial against placebo. Zeidan and colleagues report that after a median of 26 months follow-up, 27% of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-11, Vol.140 (20), p.2170-2174
Hauptverfasser:	Zeidan, Amer M., Platzbecker, Uwe, Garcia-Manero, Guillermo, Sekeres, Mikkael A., Fenaux, Pierre, DeZern, Amy E., Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit K., Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Shetty, Jeevan K., Ito, Rodrigo, Zhang, Jennie, Zhang, George, Ha, Xianwei, Backstrom, Jay T., Komrokji, Rami S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Activin Receptors, Type II Humans Immunoglobulin Fc Fragments Myelodysplastic Syndromes - therapy Recombinant Fusion Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!